{(1S)1-[4-(ethoxycarbonyl)phenyl]ethyl}hydrazinium chloride | 875558-57-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {(1S)1-[4-(ethoxycarbonyl)phenyl]ethyl}hydrazinium chloride
• 英文别名: ethyl 4-[(1S)-1-hydrazinoethyl]benzoate hydrochloride；ethyl 4-[(1S)-1-hydrazinylethyl]benzoate;hydrochloride
• CAS: 875558-57-9
• 化学式: C₁₁H₁₆N₂O₂*ClH
• 分子量: 244.721
• InChiKey: BNOFDUIJNPZOHP-QRPNPIFTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.81
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  64.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {(1S)1-[4-(ethoxycarbonyl)phenyl]ethyl}hydrazinium chloride 在 四(三苯基膦)钯 、 溶剂黄146 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙二醇二甲醚 为溶剂， 反应 9.17h， 生成
  参考文献：
  名称：

  Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes

  摘要：

  A potent, selective glucagon receptor antagonist 9m, N-[(4-{(1S)-1-[3-(3,5-dichlorophenyl) -5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)-carbonyl]-beta-alanine, was discovered by optimization of a previously identified lead. Compound 9m is a reversible and competitive antagonist with high binding affinity (IC50 of 6.6 nM) and functional cAMP activity (IC50 of 15.7 nM). It is selective for glucagon receptor relative to other family B GPCRs, showing IC50 values of 1020 nM for GIPR, 9200 nM for PAC1, and >10000 nM for GLP-1R, VPAC1, and VPAC2. Compound 9m blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It also lowered ambient glucose levels in both acute and chronic mouse models: in hGCGR ob/ob mice it reduced glucose (AUC 0-6 h) by 32% and 39% at 3 and 10 mpk single doses, respectively. In hGCGR mice on a high fat diet, compound 9m at 3, and 10 mpk po in feed lowered blood glucose levels by 89% and 94% at day 10, respectively, relative to the difference between the vehicle control and lean hGCGR mice. On the basis of its favorable biological and DMPK properties, compound 9m (MK-0893) was selected for further preclinical and clinical evaluations.

  DOI：

  10.1021/jm300579z

文献信息

• Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use
  申请人：Brockunier Linda

  公开号：US20080108620A1

  公开（公告）日：2008-05-08

  The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.

  本发明涉及取代吡唑，含有此类化合物的组合物以及治疗方法。这些化合物是胰高血糖素受体拮抗剂，因此可用于治疗、预防或延迟2型糖尿病的发生。
• Substituted pyrazoles, compositions containing such compounds and methods of use
  申请人：Merck & Co., Inc.

  公开号：US07625938B2

  公开（公告）日：2009-12-01

  The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.

  本发明涉及取代的吡唑，包含这种化合物的组合物和治疗方法。这些化合物是胰高血糖素受体拮抗剂，因此可用于治疗、预防或延缓2型糖尿病的发生。
• [EN] SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE<br/>[FR] PYRAZOLES SUBSTITUES, COMPOSITIONS CONTENANT DE TELS COMPOSES ET LEURS METHODES D'UTILISATION
  申请人：MERCK & CO INC

  公开号：WO2006014618A3

  公开（公告）日：2006-10-19
• SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1773330B1

  公开（公告）日：2010-05-26
• EP1773330A4
  申请人：——

  公开号：EP1773330A4

  公开（公告）日：2009-01-21